Related Experiment Video

Updated: Nov 15, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.5K

Ixazomib inhibits myeloma cell proliferation by targeting UBE2K

Qingqing Wang1, Zhigao Dong1, Junnan Su1

  • 1Blood Rheumatism Immunology Department, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China.

Biochemical and Biophysical Research Communications
|March 1, 2021
PubMed
Abstract

Insights

Ixazomib impairs multiple myeloma cell proliferation by targeting Ubiquitin-conjugating enzyme E2 (UBE2K). This proteasome inhibitor reduces cell survival and induces apoptosis by downregulating UBE2K expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ixazomib is an approved proteasome inhibitor for multiple myeloma treatment.
  • Ubiquitin-conjugating enzyme E2 (UBE2K) plays a role in tumor cell survival and is a drug target.
  • Understanding ixazomib's interaction with UBE2K is crucial for myeloma therapy.

Purpose of the Study:

  • To investigate the relationship between ixazomib and UBE2K in multiple myeloma cells.
  • To elucidate the mechanism by which ixazomib affects UBE2K expression and function.
  • To determine the impact of ixazomib-induced UBE2K modulation on myeloma cell behavior.

Main Methods:

  • Cell viability and apoptosis assays (CCK-8, Annexin V-FITC/PI) were performed on myeloma cell lines.
  • Quantitative PCR and Western blot analyzed gene and protein expression changes post-ixazomib treatment.
  • UBE2K overexpression studies assessed ixazomib's regulatory effects on UBE2K and downstream targets.

Main Results:

  • Ixazomib decreased myeloma cell survival and increased apoptosis in a dose-dependent manner.
  • Ixazomib altered the expression of several genes, including downregulation of UBE2K and upregulation of HIST1H2BD, MNAT1, NEK3, and TARS2.
  • Inhibition of UBE2K by ixazomib suppressed myeloma cell proliferation, arrested the cell cycle, induced apoptosis, and increased reactive oxygen species production.

Conclusions:

  • Ixazomib impairs multiple myeloma cell proliferation through the inhibition of UBE2K.
  • Ixazomib modulates mitosis- and apoptosis-related genes by reducing UBE2K expression.
  • Targeting UBE2K represents a potential therapeutic strategy for multiple myeloma using ixazomib.
Keywords:
Multiple myelomaProteasome inhibitorReactive oxygen speciesUbiquitin proteasome system

More Related Videos

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

2.9K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.4K